English
简体中文
Total: £ 56.28
Published Date: 2025-06-27 | Pages: 76 | Tables: 80 | New Technology
The global market for siRNA Drugs was valued at US$ 2443 million in the year 2024 and is projected to reach a revised size of US$ 16238 million by 2031, growing at a CAGR of 28.9% during the forecast period.
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
"The 14th Five-Year Plan for the Development of the Pharmaceutical Industry": Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide "one-stop" services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the "patent pool" model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
This report aims to provide a comprehensive presentation of the global market for siRNA Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding siRNA Drugs.
The siRNA Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global siRNA Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the siRNA Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam
Novartis
Novo Nordisk
Genzyme
Arrowhead
Silence
Sylentis
Avidity Biosciences
Sirnaomics
Segment by Type
Intravenous Injection
Subcutaneous Injection
Segment by Application
Nervous System Therapy
Endocrine and Metabolic Therapy
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of siRNA Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global siRNA Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Intravenous Injection
1.2.3 Subcutaneous Injection
1.3 Market by Application
1.3.1 Global siRNA Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Nervous System Therapy
1.3.3 Endocrine and Metabolic Therapy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global siRNA Drugs Market Perspective (2020-2031)
2.2 Global siRNA Drugs Growth Trends by Region
2.2.1 Global siRNA Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 siRNA Drugs Historic Market Size by Region (2020-2025)
2.2.3 siRNA Drugs Forecasted Market Size by Region (2026-2031)
2.3 siRNA Drugs Market Dynamics
2.3.1 siRNA Drugs Industry Trends
2.3.2 siRNA Drugs Market Drivers
2.3.3 siRNA Drugs Market Challenges
2.3.4 siRNA Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top siRNA Drugs Players by Revenue
3.1.1 Global Top siRNA Drugs Players by Revenue (2020-2025)
3.1.2 Global siRNA Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top siRNA Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by siRNA Drugs Revenue
3.4 Global siRNA Drugs Market Concentration Ratio
3.4.1 Global siRNA Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by siRNA Drugs Revenue in 2024
3.5 Global Key Players of siRNA Drugs Head office and Area Served
3.6 Global Key Players of siRNA Drugs, Product and Application
3.7 Global Key Players of siRNA Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 siRNA Drugs Breakdown Data by Type
4.1 Global siRNA Drugs Historic Market Size by Type (2020-2025)
4.2 Global siRNA Drugs Forecasted Market Size by Type (2026-2031)
5 siRNA Drugs Breakdown Data by Application
5.1 Global siRNA Drugs Historic Market Size by Application (2020-2025)
5.2 Global siRNA Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America siRNA Drugs Market Size (2020-2031)
6.2 North America siRNA Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America siRNA Drugs Market Size by Country (2020-2025)
6.4 North America siRNA Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe siRNA Drugs Market Size (2020-2031)
7.2 Europe siRNA Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe siRNA Drugs Market Size by Country (2020-2025)
7.4 Europe siRNA Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific siRNA Drugs Market Size (2020-2031)
8.2 Asia-Pacific siRNA Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific siRNA Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific siRNA Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America siRNA Drugs Market Size (2020-2031)
9.2 Latin America siRNA Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America siRNA Drugs Market Size by Country (2020-2025)
9.4 Latin America siRNA Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa siRNA Drugs Market Size (2020-2031)
10.2 Middle East & Africa siRNA Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa siRNA Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa siRNA Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam Business Overview
11.1.3 Alnylam siRNA Drugs Introduction
11.1.4 Alnylam Revenue in siRNA Drugs Business (2020-2025)
11.1.5 Alnylam Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis siRNA Drugs Introduction
11.2.4 Novartis Revenue in siRNA Drugs Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk siRNA Drugs Introduction
11.3.4 Novo Nordisk Revenue in siRNA Drugs Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Genzyme
11.4.1 Genzyme Company Details
11.4.2 Genzyme Business Overview
11.4.3 Genzyme siRNA Drugs Introduction
11.4.4 Genzyme Revenue in siRNA Drugs Business (2020-2025)
11.4.5 Genzyme Recent Development
11.5 Arrowhead
11.5.1 Arrowhead Company Details
11.5.2 Arrowhead Business Overview
11.5.3 Arrowhead siRNA Drugs Introduction
11.5.4 Arrowhead Revenue in siRNA Drugs Business (2020-2025)
11.5.5 Arrowhead Recent Development
11.6 Silence
11.6.1 Silence Company Details
11.6.2 Silence Business Overview
11.6.3 Silence siRNA Drugs Introduction
11.6.4 Silence Revenue in siRNA Drugs Business (2020-2025)
11.6.5 Silence Recent Development
11.7 Sylentis
11.7.1 Sylentis Company Details
11.7.2 Sylentis Business Overview
11.7.3 Sylentis siRNA Drugs Introduction
11.7.4 Sylentis Revenue in siRNA Drugs Business (2020-2025)
11.7.5 Sylentis Recent Development
11.8 Avidity Biosciences
11.8.1 Avidity Biosciences Company Details
11.8.2 Avidity Biosciences Business Overview
11.8.3 Avidity Biosciences siRNA Drugs Introduction
11.8.4 Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025)
11.8.5 Avidity Biosciences Recent Development
11.9 Sirnaomics
11.9.1 Sirnaomics Company Details
11.9.2 Sirnaomics Business Overview
11.9.3 Sirnaomics siRNA Drugs Introduction
11.9.4 Sirnaomics Revenue in siRNA Drugs Business (2020-2025)
11.9.5 Sirnaomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global siRNA Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Intravenous Injection
Table 3. Key Players of Subcutaneous Injection
Table 4. Global siRNA Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global siRNA Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global siRNA Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global siRNA Drugs Market Share by Region (2020-2025)
Table 8. Global siRNA Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global siRNA Drugs Market Share by Region (2026-2031)
Table 10. siRNA Drugs Market Trends
Table 11. siRNA Drugs Market Drivers
Table 12. siRNA Drugs Market Challenges
Table 13. siRNA Drugs Market Restraints
Table 14. Global siRNA Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global siRNA Drugs Market Share by Players (2020-2025)
Table 16. Global Top siRNA Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)
Table 17. Ranking of Global Top siRNA Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by siRNA Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of siRNA Drugs, Headquarters and Area Served
Table 20. Global Key Players of siRNA Drugs, Product and Application
Table 21. Global Key Players of siRNA Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global siRNA Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global siRNA Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global siRNA Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global siRNA Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global siRNA Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global siRNA Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America siRNA Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America siRNA Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America siRNA Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe siRNA Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe siRNA Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe siRNA Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific siRNA Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific siRNA Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific siRNA Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America siRNA Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America siRNA Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America siRNA Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa siRNA Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa siRNA Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa siRNA Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Alnylam Company Details
Table 47. Alnylam Business Overview
Table 48. Alnylam siRNA Drugs Product
Table 49. Alnylam Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 50. Alnylam Recent Development
Table 51. Novartis Company Details
Table 52. Novartis Business Overview
Table 53. Novartis siRNA Drugs Product
Table 54. Novartis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Novo Nordisk Company Details
Table 57. Novo Nordisk Business Overview
Table 58. Novo Nordisk siRNA Drugs Product
Table 59. Novo Nordisk Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 60. Novo Nordisk Recent Development
Table 61. Genzyme Company Details
Table 62. Genzyme Business Overview
Table 63. Genzyme siRNA Drugs Product
Table 64. Genzyme Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 65. Genzyme Recent Development
Table 66. Arrowhead Company Details
Table 67. Arrowhead Business Overview
Table 68. Arrowhead siRNA Drugs Product
Table 69. Arrowhead Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 70. Arrowhead Recent Development
Table 71. Silence Company Details
Table 72. Silence Business Overview
Table 73. Silence siRNA Drugs Product
Table 74. Silence Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 75. Silence Recent Development
Table 76. Sylentis Company Details
Table 77. Sylentis Business Overview
Table 78. Sylentis siRNA Drugs Product
Table 79. Sylentis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 80. Sylentis Recent Development
Table 81. Avidity Biosciences Company Details
Table 82. Avidity Biosciences Business Overview
Table 83. Avidity Biosciences siRNA Drugs Product
Table 84. Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 85. Avidity Biosciences Recent Development
Table 86. Sirnaomics Company Details
Table 87. Sirnaomics Business Overview
Table 88. Sirnaomics siRNA Drugs Product
Table 89. Sirnaomics Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 90. Sirnaomics Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. Authors List of This Report
List of Figures
Figure 1. siRNA Drugs Picture
Figure 2. Global siRNA Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global siRNA Drugs Market Share by Type: 2024 VS 2031
Figure 4. Intravenous Injection Features
Figure 5. Subcutaneous Injection Features
Figure 6. Global siRNA Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global siRNA Drugs Market Share by Application: 2024 VS 2031
Figure 8. Nervous System Therapy Case Studies
Figure 9. Endocrine and Metabolic Therapy Case Studies
Figure 10. Others Case Studies
Figure 11. siRNA Drugs Report Years Considered
Figure 12. Global siRNA Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global siRNA Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global siRNA Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global siRNA Drugs Market Share by Players in 2024
Figure 16. Global siRNA Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by siRNA Drugs Revenue in 2024
Figure 18. North America siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America siRNA Drugs Market Share by Country (2020-2031)
Figure 20. United States siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe siRNA Drugs Market Share by Country (2020-2031)
Figure 24. Germany siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Ireland siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific siRNA Drugs Market Share by Region (2020-2031)
Figure 32. China siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia & New Zealand siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America siRNA Drugs Market Share by Country (2020-2031)
Figure 40. Mexico siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa siRNA Drugs Market Share by Country (2020-2031)
Figure 44. Israel siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE siRNA Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Alnylam Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 48. Novartis Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 49. Novo Nordisk Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 50. Genzyme Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 51. Arrowhead Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 52. Silence Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 53. Sylentis Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 54. Avidity Biosciences Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 55. Sirnaomics Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
